Cargando…
Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?
Autor principal: | Bloomgarden, Zachary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509509/ https://www.ncbi.nlm.nih.gov/pubmed/37727016 http://dx.doi.org/10.1111/1753-0407.13469 |
Ejemplares similares
-
Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017) -
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023) -
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
por: Patel Chavez, Chandani, et al.
Publicado: (2021) -
Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)